Related references
Note: Only part of the references are listed.Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients
A. Sanchez Fructuoso et al.
TRANSPLANTATION PROCEEDINGS (2007)
Impact on renal function of the use of sirolimus in cardiac transplantation
M. Ubilla et al.
TRANSPLANTATION PROCEEDINGS (2007)
The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy
Robert T. Abraham et al.
CLINICAL CANCER RESEARCH (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Use of sirolimus in solid organ transplantation
Joshua J. Augustine et al.
DRUGS (2007)
Temsirolimus in the treatment of advanced renal cell carcinoma
M. E. Gore
ANNALS OF ONCOLOGY (2007)
Sirolimus - Challenging current perspectives
Irina Buhaescu et al.
THERAPEUTIC DRUG MONITORING (2006)
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus
I. Duran et al.
EUROPEAN JOURNAL OF CANCER (2006)
Antianglogenic potential of the mammalian target of rapamycin inhibitor temsirolimus
Donatella Del Bufalo et al.
CANCER RESEARCH (2006)
Sirolimus-associated proteinuria and renal dysfunction
Gopala K. Rangan
DRUG SAFETY (2006)
Population pharmacokinetics of CCI-779: Correlations to safety and pharmacogenomic responses in patients with advanced renal cancer
JP Boni et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
MB Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
E Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E
DC Fingar et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin
CC Hudson et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Share Paper
